Business · 28/04/2004
FDA Releases Draft Guidance for Exocrine Pancreatic Insufficiency Drug Products
The Food and Drug Administration (FDA) has made available a draft guidance document to help pharmaceutical companies submit new drug applications for exocrine pancreatic insufficiency drug products, which are now classified as new drugs requiring approved NDAs for marketing.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →